Supplemental Financial Information (Tables)

12 Months Ended

Dec. 31, 2020

Balance Sheet Related Disclosures [Abstract]

Schedule of Accrued Expenses and Other Current Labilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

	December 31,		December 31,
	2020		2019
Accrued research and development	$	2,106	$	7
Accrued compensation		1,766		—
Accrued professional fees		999		122
Other		264		21
Total accrued expenses and other current liabilities	$	5,135	$	150

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

	December 31,		December 31,
	2020		2019
Prepaid insurance	$	2,480	$	—
Prepaid research and development		2,462		—
Prepaid clinical trial		944		—
Other		740		—
Total prepaid expenses and other current assets	$	6,626	$	—